Our Blog

News & Events
You are here:

Job offer – Research assistant

  Location: UK / home based Position : 40 hours per week / permanent Travel required: 10 days / year (approx.) Gross Salary Range: £28,000– £33,000 depending on experience Starting date: hiring immediately   We are seeking a Research Assistant to support the research activities of the Patient Evidence Department of Myeloma Patients Europe (MPE). Please, send your CV and cover letter at . Applications without a cover letter will be rejected.  The following tasks and core…

Read Article

Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”

  Myeloma Patients Europe (MPE) held a webinar to summarise the most important AL amyloidosis updates and share patient experiences with therapies like CAR-T and CAEL-101.  The webinar took place on 16th April 2024 and was given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein. Watch the recording below:  

Read Article

European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

  The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD – such as lenalidomide and pomalidomide) and a proteasome inhibitor (PI – such as bortezomib or carfilzomib), have demonstrated disease progression on the last therapy and are refractory (i.e. no longer responding) to lenalidomide. This follows an earlier…

Read Article

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

  Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search of clinical trials for these conditions and provide to patients, carers and…

Read Article

Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myeloma

  Last Friday, the US FDA’s Oncology Drugs Advisory Committee (ODAC) (FDA being the US medicines regulator) voted 12 – 0 to approve minimal residual disease (MRD) as an accepted endpoint for accelerated approval of new myeloma drugs. The committee’s primary role is to review benefit-risk data of new cancer drugs. You can see the full meeting and evidence considered here. The decision means that myeloma drugs may now be approved earlier in the US…

Read Article